San Carlos, United States
Clear Labs, founded in 2014 and headquartered in the United States, is at the forefront of simplifying complex diagnostics through its fully automated next-generation sequencing (NGS) platforms. With a slogan as compelling as "Provider of fully automated next generation sequencing platforms, software and robotics for turnkey diagnostics," the company offers sophisticated solutions that integrate DNA sequencing, robotics, and cloud-based analytics to deliver enhanced clarity and speed in diagnosing various pathogens.
The firm's comprehensive platform is revolutionary, enabling faster outcomes and heightened accuracy, especially in tackling food-borne pathogens and infectious diseases like SARS CoV-2. This aligns precisely with industry trends towards democratizing genomics applications and catering to both clinical and applied markets.
Clear Labs recently secured a significant $30.00M Series D investment on 13 January 2025, with an impressive roster of backers including Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, T. Rowe Price, HBM Genomics, Wing Venture Capital, Google Ventures, Felicis, and Counterpoint Global. This funding round highlights robust investor confidence and positions Clear Labs for further growth in the intersection of AI, Biotechnology, and Health Care.
